Tracer Biotechnologies Announces Strategic Partnership with QIAGEN to Advance Blood-Based MRD Testing for Solid Tumors
Tracer Biotechnologies, a leader in blood-based molecular diagnostics for cancer, is pleased to announce a strategic partnership with QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) to co-develop and commercialize minimal residual disease (MRD) assays for solid tumors on QIAGEN’s QIAcuity digital PCR platform.
Tracer Biotechnologies Announces Agreement for Next-Generation Cancer Monitoring for Drug Development
Tracer Biotechnologies, a next-generation diagnostics company, today announced a multi-year project with AstraZeneca (LSE/STO/Nasdaq: AZN).
